Abstract
Background The management of pT1a-b pN0 HER2-positive breast cancer is controversial and no data about the efficacy of trastuzumab in this setting are available from randomized clinical trials. The aims of this retrospective study were to assess how patients are managed in clinical practice in Italy, which clinical or biological characteristics influenced the choice of adjuvant systemic therapy and the outcome of patients. Methods Data of consecutive patients who underwent surgery from January 2007 to December 2012 for HER2-positive, pT1a-b pN0 M0 breast cancer were retrospectively collected from 28Italian centres. Analysis of contingency tables and multivariate generalized logit models were used to investigate the association between the baseline clinical and biological features and the treatment strategy adopted. Results Among 303 enrolled patients, 204 received adjuvant systemic therapy with trastuzumab, 65 adjuvant systemic therapy without trastuzumab and 34 did not receive adjuvant systemic therapy. At the multivariate analysis age, tumor size, proliferation index and hormone receptor status were significantly associated with the treatment choice. Five-year disease-free survival (DFS) probability was 95%, 94.3% and 69.6% for patients treated with adjuvant systemic therapy and trastuzumab, with adjuvant systemic therapy without trastuzumab and for patients who did not receive adjuvant systemic therapy, respectively (p
| Original language | English |
|---|---|
| Article number | e0136731 |
| Journal | PLoS One |
| Volume | 10 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - Sep 4 2015 |
Fingerprint
ASJC Scopus subject areas
- Agricultural and Biological Sciences(all)
- Biochemistry, Genetics and Molecular Biology(all)
- Medicine(all)
Cite this
The promher study : An observational Italian study on adjuvant therapy for her2-positive, pT1a-b pN0 breast cancer. / Gori, Stefania; Inno, Alessandro; Fiorio, Elena; Foglietta, Jennifer; Ferro, Antonella; Gulisano, Marcella; Pinotti, Graziella; Gubiotti, Marta; Cavazzini, Maria Giovanna; Turazza, Monica; Duranti, Simona; De Simone, Valeria; Iezzi, Laura; Bisagni, Giancarlo; Spazzapan, Simon; Cavanna, Luigi; Saggia, Chiara; Bria, Emilio; Cretella, Elisabetta; Vici, Patrizia; Santini, Daniele; Fabi, Alessandra; Garrone, Ornella; Frassoldati, Antonio; Amaducci, Laura; Saracchini, Silvana; Evangelisti, Lucia; Barni, Sandro; Gamucci, Teresa; Mentuccia, Lucia; Laudadio, Lucio; Zoboli, Alessandra; Marchetti, Fabiana; Bogina, Giuseppe; Lunardi, Gianluigi; Boni, Luca.
In: PLoS One, Vol. 10, No. 9, e0136731, 04.09.2015.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The promher study
T2 - An observational Italian study on adjuvant therapy for her2-positive, pT1a-b pN0 breast cancer
AU - Gori, Stefania
AU - Inno, Alessandro
AU - Fiorio, Elena
AU - Foglietta, Jennifer
AU - Ferro, Antonella
AU - Gulisano, Marcella
AU - Pinotti, Graziella
AU - Gubiotti, Marta
AU - Cavazzini, Maria Giovanna
AU - Turazza, Monica
AU - Duranti, Simona
AU - De Simone, Valeria
AU - Iezzi, Laura
AU - Bisagni, Giancarlo
AU - Spazzapan, Simon
AU - Cavanna, Luigi
AU - Saggia, Chiara
AU - Bria, Emilio
AU - Cretella, Elisabetta
AU - Vici, Patrizia
AU - Santini, Daniele
AU - Fabi, Alessandra
AU - Garrone, Ornella
AU - Frassoldati, Antonio
AU - Amaducci, Laura
AU - Saracchini, Silvana
AU - Evangelisti, Lucia
AU - Barni, Sandro
AU - Gamucci, Teresa
AU - Mentuccia, Lucia
AU - Laudadio, Lucio
AU - Zoboli, Alessandra
AU - Marchetti, Fabiana
AU - Bogina, Giuseppe
AU - Lunardi, Gianluigi
AU - Boni, Luca
PY - 2015/9/4
Y1 - 2015/9/4
N2 - Background The management of pT1a-b pN0 HER2-positive breast cancer is controversial and no data about the efficacy of trastuzumab in this setting are available from randomized clinical trials. The aims of this retrospective study were to assess how patients are managed in clinical practice in Italy, which clinical or biological characteristics influenced the choice of adjuvant systemic therapy and the outcome of patients. Methods Data of consecutive patients who underwent surgery from January 2007 to December 2012 for HER2-positive, pT1a-b pN0 M0 breast cancer were retrospectively collected from 28Italian centres. Analysis of contingency tables and multivariate generalized logit models were used to investigate the association between the baseline clinical and biological features and the treatment strategy adopted. Results Among 303 enrolled patients, 204 received adjuvant systemic therapy with trastuzumab, 65 adjuvant systemic therapy without trastuzumab and 34 did not receive adjuvant systemic therapy. At the multivariate analysis age, tumor size, proliferation index and hormone receptor status were significantly associated with the treatment choice. Five-year disease-free survival (DFS) probability was 95%, 94.3% and 69.6% for patients treated with adjuvant systemic therapy and trastuzumab, with adjuvant systemic therapy without trastuzumab and for patients who did not receive adjuvant systemic therapy, respectively (p
AB - Background The management of pT1a-b pN0 HER2-positive breast cancer is controversial and no data about the efficacy of trastuzumab in this setting are available from randomized clinical trials. The aims of this retrospective study were to assess how patients are managed in clinical practice in Italy, which clinical or biological characteristics influenced the choice of adjuvant systemic therapy and the outcome of patients. Methods Data of consecutive patients who underwent surgery from January 2007 to December 2012 for HER2-positive, pT1a-b pN0 M0 breast cancer were retrospectively collected from 28Italian centres. Analysis of contingency tables and multivariate generalized logit models were used to investigate the association between the baseline clinical and biological features and the treatment strategy adopted. Results Among 303 enrolled patients, 204 received adjuvant systemic therapy with trastuzumab, 65 adjuvant systemic therapy without trastuzumab and 34 did not receive adjuvant systemic therapy. At the multivariate analysis age, tumor size, proliferation index and hormone receptor status were significantly associated with the treatment choice. Five-year disease-free survival (DFS) probability was 95%, 94.3% and 69.6% for patients treated with adjuvant systemic therapy and trastuzumab, with adjuvant systemic therapy without trastuzumab and for patients who did not receive adjuvant systemic therapy, respectively (p
UR - http://www.scopus.com/inward/record.url?scp=84945217649&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84945217649&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0136731
DO - 10.1371/journal.pone.0136731
M3 - Article
AN - SCOPUS:84945217649
VL - 10
JO - PLoS One
JF - PLoS One
SN - 1932-6203
IS - 9
M1 - e0136731
ER -